J 2016

Whole genome amplification effect on segmental copy-number changes and copy-number neutral loss of heterozygosity analysis by oligonucleotide-array based comparative genomic hybridization in human myeloma cell line

MIKULÁŠOVÁ, Aneta, Jan SMETANA, Markéta WAYHELOVÁ, Helena JANYŠKOVÁ, Samuel Adeyinka OKUBOTE et. al.

Základní údaje

Originální název

Whole genome amplification effect on segmental copy-number changes and copy-number neutral loss of heterozygosity analysis by oligonucleotide-array based comparative genomic hybridization in human myeloma cell line

Autoři

MIKULÁŠOVÁ, Aneta (203 Česká republika, domácí), Jan SMETANA (203 Česká republika, domácí), Markéta WAYHELOVÁ (203 Česká republika, domácí), Helena JANYŠKOVÁ (203 Česká republika, domácí), Samuel Adeyinka OKUBOTE (566 Nigérie, domácí), Roman HÁJEK (203 Česká republika) a Petr KUGLÍK (203 Česká republika, garant, domácí)

Vydání

International Journal of Clinical and Experimental Pathology, 2016, 1936-2625

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

Genetika a molekulární biologie

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.706

Kód RIV

RIV/00216224:14310/16:00088952

Organizační jednotka

Přírodovědecká fakulta

UT WoS

000381729200036

Klíčová slova anglicky

whole genome amplification; array-comparative genomic hybridization; copy-number changes

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 26. 4. 2017 23:13, Ing. Andrea Mikešková

Anotace

V originále

Whole genome amplification (WGA) is an approach designed to overcome small amounts of DNA for genome-wide genetic tests used in many clinical applications. Various strategies of WGA have been developed; however, none of them can guarantee the absence of amplification bias. In this study, a total of 4 multiple displacement amplification (MDA)-based and 2 PCR-based WGA kits were compared in their effect on segmental copy-number (CN) changes and copy-number neutral loss of heterozygosity (cnnLOH) detection by 3 microarray platforms: CGH/4×44 K (Agilent), CGH+SNP/4×180 K (Agilent) and CGH+SNP/4×180 K (OGT). Genomic imbalances-rich myeloma cell line U266 was used as material. The main outcomes are as follows: 1) MDA-based WGAs showed higher tendency to generate false positive imbalances in contrast to PCR-based WGAs with higher risk of false negativity; 2) the specific risk of false positivity and/or negativity increased with decreasing CN segments size; 3) single-cell WGAs showed significantly worse effect on results in comparison to WGAs with nanogram level of DNA as input; 4) PCR-based WGAs were incompatible with cnnLOH analysis based on SNP in restriction digestion sites and also showed higher risk of cnnLOH false negativity when combined with analysis based on simple hybridization. In conclusion, the results of this study help to choose WGA according to individual user requirements and options. Moreover, we have shown a strategy to verify and validate segmental CN changes detection by DNA array protocol including any WGA for any purpose to attain the highest efficiency without an unnecessary WGA bias.

Návaznosti

NT13492, projekt VaV
Název: Úloha genetických abnormalit ve vývoji a progresi prekancerózy monoklonální gamapatie nejasného významu